Los Angeles Capital Management LLC Purchases Shares of 134,998 Exact Sciences Corporation $EXAS

Los Angeles Capital Management LLC acquired a new position in Exact Sciences Corporation (NASDAQ:EXAS) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 134,998 shares of the medical research company’s stock, valued at approximately $7,174,000.

Several other institutional investors have also recently added to or reduced their stakes in EXAS. Larson Financial Group LLC lifted its stake in Exact Sciences by 2,804.8% during the first quarter. Larson Financial Group LLC now owns 610 shares of the medical research company’s stock worth $26,000 after purchasing an additional 589 shares in the last quarter. National Pension Service grew its stake in shares of Exact Sciences by 75.1% in the first quarter. National Pension Service now owns 681 shares of the medical research company’s stock valued at $29,000 after buying an additional 292 shares in the last quarter. SVB Wealth LLC purchased a new stake in shares of Exact Sciences in the 1st quarter valued at $30,000. True Wealth Design LLC raised its holdings in shares of Exact Sciences by 951.8% in the 2nd quarter. True Wealth Design LLC now owns 589 shares of the medical research company’s stock valued at $31,000 after buying an additional 533 shares during the period. Finally, Banque Cantonale Vaudoise acquired a new position in Exact Sciences during the 1st quarter worth about $34,000. Institutional investors and hedge funds own 88.82% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on EXAS shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Exact Sciences in a research note on Wednesday, October 8th. UBS Group dropped their price objective on shares of Exact Sciences from $61.00 to $53.00 and set a “neutral” rating for the company in a report on Thursday, August 7th. Craig Hallum upped their target price on shares of Exact Sciences from $65.00 to $85.00 and gave the stock a “buy” rating in a research note on Thursday, September 11th. Stifel Nicolaus boosted their price target on shares of Exact Sciences from $67.00 to $80.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Finally, Wall Street Zen lowered Exact Sciences from a “buy” rating to a “hold” rating in a research report on Saturday. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $73.44.

Insiders Place Their Bets

In other Exact Sciences news, EVP Brian Baranick sold 2,858 shares of the stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $70.08, for a total value of $200,288.64. Following the completion of the transaction, the executive vice president directly owned 22,368 shares of the company’s stock, valued at approximately $1,567,549.44. This trade represents a 11.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director James Edward Doyle sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, October 9th. The stock was sold at an average price of $60.00, for a total value of $120,000.00. Following the completion of the sale, the director owned 57,962 shares in the company, valued at approximately $3,477,720. This represents a 3.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 6,343 shares of company stock valued at $382,688. 1.20% of the stock is owned by insiders.

Exact Sciences Price Performance

Exact Sciences stock opened at $66.18 on Monday. The company has a current ratio of 2.89, a quick ratio of 2.56 and a debt-to-equity ratio of 0.94. The company has a fifty day simple moving average of $58.09 and a 200-day simple moving average of $53.53. The stock has a market cap of $12.54 billion, a P/E ratio of -12.19, a price-to-earnings-growth ratio of 5.56 and a beta of 1.34. Exact Sciences Corporation has a 12-month low of $38.81 and a 12-month high of $72.81.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.13 by $0.11. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.The business had revenue of $850.74 million for the quarter, compared to the consensus estimate of $810.42 million. During the same quarter in the prior year, the business posted ($0.21) EPS. The business’s revenue for the quarter was up 20.0% on a year-over-year basis. Exact Sciences has set its FY 2025 guidance at EPS. Equities analysts expect that Exact Sciences Corporation will post -0.58 EPS for the current fiscal year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.